Friday 31 October 2025
Internal Reference Number: FOI_8859
Date Request Received: 18/08/2025 00:00:00
Date Request Replied To: 23/10/2025 00:00:00
This response was sent via: By Email
Request Summary: Coagulation Factors
Request Category: Companies
| Question Number 1: I am writing to submit a Freedom of Information (FOI) request regarding the use of coagulation factor products, specifically Bypassing Agents (BPAs; NovoSeven, FEIBA, Cevenfacta, and Obizur) and Hemlibra, to treat hemophilia and related conditions at Salisbury NHS Foundation Trust Please provide data for the period January through June 2025, as outlined below. Where feasible, please supply data split by month and patient group, and include the full tables for each section as per the attached example. How many patients did you treat with Bypassing agents (BPA)/Hemlibra inhibitor in (January, February, March, April, May and June 2025)? a. With BPA/Hemlibra Inhibitor? | |
| Answer To Question 1: <5 | |
| Question Number 2: Please fill in the BPA/Hemlibra products utilized in January, February, March, April, May and June 2025)? Please see attached | |
| Answer To Question 2: Response as attached. To accompany this answer to question 2 please also see the documents listed below:  FOI 8859 - Q2.pdf | |
| Question Number 3: How many minor and major surgeries did your BPA patients have in January, February, March, April, May and June 2025)?? - Please see attached | |
| Answer To Question 3: Response as attached. To accompany this answer to question 3 please also see the documents listed below: FOI 8859 - Q3.pdf | |
| Question Number 4: How many minor and major surgeries did your BPA/Hemlibra inhibitor patients have in January, February, March, April, May and June 2025)? Please see attached | |
| Answer To Question 4: Response as attached. To accompany this answer to question 4 please also see the documents listed below: FOI 8859 - Q4.pdf | |
| Question Number 5: How many breakthrough bleeds did your Hemlibra Inhibitor patients have, and what brand were they treated with? Please see attached | |
| Answer To Question 5: Response as attached. To accompany this answer to question 5 please also see the documents listed below: FOI 8859 - Q5.pdf | |
| Question Number 6: Were there any changes in the total number of acute bleeds treated with factor in Q2’25 (April-June 2025) compared to Q1’25 (Jan–Mar 2025) If yes, please specify whether there was an increase, decrease, or no change, and provide actual numbers if available | |
| Answer To Question 6: No | |
| Question Number 7: Was there any change in the number of elective surgeries using factor in Q2’25 compared to Q1’25? Please specify the number of surgeries in both quarters and clarify if there was an increase, decrease, or no change Please see attached | |
| Answer To Question 7: Response as attached To accompany this answer to question 7 please also see the documents listed below: FOI 8859 - Q7.pdf | |
| Question Number 8: Have any BPA patients switched products between January 1st through June 2025? What were the reasons for the switches? Please see attached. | |
| Answer To Question 8: 0 - No patients switched product To accompany this answer to question 8 please also see the documents listed below:  FOI 8859 - Q8.docx | |
| Question Number 9: What is the total number of patients treated with NovoSeven at Salisbury NHS Foundation Trustfor each month (January–June 2025)? | |
| Answer To Question 9: <5 patients - Jan 2025 <5 patients in Feb/Mar/Apr/May/Jun 2025 | |
| Please see Attachments: | |
| To return to the list of all the FOI requests please click here | |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
